Microsona

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Microsona

Quick Facts

Property Description
Active ingredient Hydrocortisone
Form Cream, Ointment, Solution, Tablet
Pharmacological class Corticosteroid (Glucocorticoid)
Common use Anti-inflammatory, Immune Modulation
Origin Synthetic

Microsona is a medicine whose core function is to control inflammation and modulate the body’s immune responses, providing relief from severe irritation. Its identity is defined by its active component, Hydrocortisone, and its classification as a potent synthetic corticosteroid.


What Type of Medicine is Microsona?

Microsona is classified as a Corticosteroid, specifically belonging to the Glucocorticoid pharmacological group, which means it acts as a regulatory substance for inflammation. Its active ingredient, Hydrocortisone, is a synthetic compound created to replicate the anti-inflammatory and immunosuppressive actions of cortisol, the natural hormone produced by the adrenal glands. This unique origin as a direct cortisol analogue provides effective activity against immune-mediated symptoms. Corticosteroids primarily function as anti-inflammatory and immunosuppressive agents. This means the medicine’s main purpose is to reduce swelling and immune over-response.


Composition and Common Pharmaceutical Forms

The basis of Microsona is its single-component formulation, containing Hydrocortisone as the sole primary active medicinal agent. This compound is prepared in various high-level dosage forms, most commonly as a topical cream or ointment for skin application, which are typically used for localized symptoms. The underlying substance is also manufactured for oral (tablet) or parenteral (injection) routes of administration. The specific pharmaceutical base, whether a lighter emollient cream or a thicker occlusive ointment, defines the physical nature of the preparation and ensures the active Hydrocortisone is delivered effectively to the targeted site.


General Purpose and Core Therapeutic Function

The general purpose of Microsona is to swiftly reduce the physical signs and symptoms of an overactive or excessive immune response, specifically targeting inflammation and allergic manifestations. A common use scenario involves controlling the flare-up of irritated, itchy skin due to contact with an irritant. The drug achieves this by suppressing the release of chemical mediators that cause swelling, redness, and severe itching (anti-pruritic effect). This potent anti-inflammatory and immunomodulatory action is the core benefit delivered to the patient, focusing on controlling irritation rather than treating a specific underlying disease.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Microsona?

The official safety profile for Microsona is documented by government regulatory agencies (such as the FDA, EMA, and others) to provide a factual summary of observed adverse reactions and safety restrictions.

Adverse Reactions by Frequency and System-Organ-Class

Adverse reactions associated with the use of Microsona are categorized based on how frequently they occurred in clinical studies or post-marketing surveillance. These effects are also organized by the affected part of the body, known as System-Organ-Class (SOC) groupings, which may include the gastrointestinal system, the nervous system, or the skin.

The regulatory label outlines the frequency of these effects using terms such as Very Common (occurring in 1 in 10 patients or more), Common, Uncommon, Rare, and Very Rare.

Serious Adverse Reactions

The official labeling highlights specific serious adverse reactions—those that are life-threatening or result in significant disability. These serious risks, although often rare, are a mandatory component of the drug's safety information and are typically detailed within the Warnings and Precautions section of regulatory documents.

Safety Restrictions and Population-Specific Notes

The product's formal safety profile defines specific contraindications, which are situations or conditions where the medicine must not be used because the risk outweighs any potential benefit. Additionally, Special Warnings and Precautions outline conditions requiring particular caution, such as pre-existing medical conditions or co-treatment with other medicines.

Population-specific safety considerations, if documented, address the use of Microsona in vulnerable groups. This may include statements on the use of the medicine during pregnancy, while breastfeeding, or in specific patient populations such as children or the elderly, based exclusively on the data assessed by the governmental authority.

This structure ensures a clear, non-interpretive presentation of the medicine's risk profile, as required by regulatory bodies worldwide.

Overdose and Emergency Response

Overdose and When to Seek Help

The officially documented profile for corticosteroid overdosage, such as with Microsona, centers on two main areas: acute and chronic exposure. Acute overdosage resulting from a single, excessive dose is generally considered rare and is unlikely to cause immediate, life-threatening toxicity.


Documented Overdose Presentations

The primary concern in overdosage is chronic, prolonged exposure to doses higher than prescribed. This can lead to the systemic effects of hypercortisolism, clinically known as Cushing's Syndrome. Symptoms of chronic overdosage include cushingoid features such as moon face and truncal obesity, and may also involve fluid retention and electrolyte disturbances.

Signs of acute toxicity can include: altered mental status with agitation, convulsions, high blood pressure, and severe electrolyte imbalances. Specific effects observed in official regulatory information include the risk of HPA axis suppression, which is a suppression of the body's natural production of corticosteroids.


Emergency Response and Medical Attention

In the event of a suspected or confirmed acute overdosage, the general treatment procedure described in official documents is supportive care and immediate drug discontinuation or appropriate dose reduction. Monitoring of fluid and electrolyte status may be required.

Immediate medical help must be sought if someone has collapsed, had a seizure, has trouble breathing, or cannot be awakened. Medical attention is also required for any signs that suggest the development of Cushing's Syndrome or severe, unexplained systemic symptoms. For all cases of suspected overdosage, the national poison control helpline or emergency services (such as 911) should be called immediately for advice and emergency assistance.

Therapeutic Uses of Microsona

Quick Facts about Microsona

  • Therapeutic Domain: Plaque Psoriasis
  • Key Action: Facilitates improvement in symptoms associated with the condition.
  • Use Context: Applied on the skin (topical use) by adults.

Microsona is an approved topical medication that healthcare providers may prescribe for plaque psoriasis in adult patients. The treatment is indicated for moderate to severe chronic plaque psoriasis when individuals are candidates for systemic therapy or phototherapy, and when alternative systemic options are medically less appropriate.

The medicine is utilized to help reduce the presence of visible signs and symptoms associated with the condition. Use of Microsona can facilitate the achievement of a cleared or almost cleared skin status in some patients. It may also promote a remittive effect, supporting the maintenance of skin condition improvement for a specific period after treatment concludes.

Microsona offers a non-steroidal option for managing this skin condition, which is characterized by patches of abnormal skin. This medication is used for the specific applications outlined in its labeling for patients who require topical management of their condition.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Microsona

The eligibility profile for Microsona (Hydrocortisone) is determined by its official regulatory status, defining populations who are prohibited from use or require special limitations.

Category Regulatory Status
Populations Contraindicated Prohibited for patients with known hypersensitivity to any component or those with untreated systemic fungal infections [2.1, 2.4]. Topical use is also contraindicated for specific skin conditions like Rosacea, Perioral Dermatitis, and untreated bacterial/viral skin infections [1.1, 4.5].
Age-Related Eligibility Adult patients are approved for use [2.1]. Pediatric patients are generally permitted, but are documented as having greater susceptibility to systemic toxicity (e.g., HPA axis suppression) due to increased skin absorption; prolonged use is not recommended in children [2.1, 4.4].
Pregnancy/Lactation Status Pregnancy: Classified as Pregnancy Category C; use is permitted only if the potential benefit justifies the potential risk to the fetus [2.1]. Lactation: Hydrocortisone is secreted into breast milk; caution should be exercised [2.4].
Condition-Specific Caution Systemic forms require caution in patients with pre-existing conditions such as hypertension, diabetes mellitus, or active peptic ulcer disease [2.3]. Topical use must avoid contact with the eyes and occlusive dressings [2.1].

Connection to the overall eligibility profile: Regulatory documents establish that use is contraindicated for populations defined by specific conditions or allergies, reflecting absolute prohibitions. Other populations, such as children and pregnant women, are subject to restricted or conditional use as formally defined in official labeling to mitigate documented risks related to systemic absorption [2.1, 2.4].

What should I know about interactions with other medicines?

Microsona Interactions with other medicines and products

Official regulatory documents define the interaction profile of Microsona (Hydrocortisone) primarily through alterations in its metabolism and pharmacodynamic effects.

Category Official Regulatory Entities Constraint/Outcome
Metabolic Interactions CYP3A4 Inhibitors (e.g., Ketoconazole) Inhibit metabolism, increasing Hydrocortisone blood levels and exposure.
CYP3A4 Inducers (e.g., Phenytoin, Rifampin) Increase metabolic clearance, reducing circulating Hydrocortisone levels.
Pharmacodynamic Risk NSAIDs, Aspirin Co-administration is associated with an increased risk of gastrointestinal adverse reactions.
Antidiabetic Agents Hydrocortisone may exert a pharmacodynamic effect by increasing blood glucose concentrations.
Contraindications Live or Live, Attenuated Vaccines Administration is contraindicated when the patient is receiving immunosuppressive doses.
Systemic Fungal Infections Use is avoided/contraindicated as it may exacerbate the infection.
Food/Herbal Products Grapefruit Juice May inhibit Hydrocortisone metabolism, potentially increasing its blood levels.
St. John's Wort Can enhance the metabolic clearance of Hydrocortisone, reducing circulating levels.

Co-administration with Estrogen-containing products may necessitate adjustments due to altered Hydrocortisone exposure. Furthermore, an enhanced effect of the corticosteroid is officially documented in patient populations with underlying conditions such as hypothyroidism and cirrhosis. These statements define the mandatory interaction information required by government labeling.

Mechanism of Action

Selective Inhibition of Cathepsin K (CTSK)

Microsona directly targets and inhibits the activity of mature osteoclasts. The compound acts as a selective inhibitor of the lysosomal cysteine protease Cathepsin K (CTSK). Microsona exhibits high affinity for the CTSK active site, functioning as a competitive inhibitor.

Modulating the Bone Resorption Cascade

Inhibition of Cathepsin K prevents the enzyme from degrading the type I collagen and other non-collagenous proteins of the organic bone matrix. This specific molecular action interrupts the osteoclast's ability to resorb bone.

Physiological Outcome and Pathway Distinction

The resultant decrease in bone resorption lessens the rate of bone mineral density loss. This reduced resorption alters the balance between bone formation and resorption. Microsona does not modulate the entire RANK/RANKL signaling axis.

Dosage and Administration Information

How to Use Microsona

Microsona (Hydrocortisone) administration is based on established protocols that vary based on the required route and systemic need. The medicine is utilized for Oral, Topical, and Parenteral (intravenous or intramuscular) applications.


Official Administration Guidelines

Category Usage Principle
Route Versatility The medicine is administered topically (cream/ointment) for localized skin conditions, or systemically (oral/parenteral) for internal inflammatory needs.
Standard Dosing Topical application is typically a thin film applied to the affected area two to four times daily. Oral systemic doses commonly begin in the 20 mg to 240 mg per day range.
Timing & Frequency The total oral dose is often divided and taken two to four times per day, and should be administered with or after food to mitigate gastrointestinal upset. Acute parenteral doses (e.g., 100 mg to 500 mg) may be repeated at 2, 4, or 6-hour intervals.
Special Handling Parenteral powder requires reconstitution and, for IV administration, must be given slowly, over 30 seconds to 10 minutes. Oral granules or certain tablets must not be crushed or chewed to preserve their intended release characteristics.
Dose Adjustments Dosing for pediatric patients is often calculated based on body surface area (BSA) or weight, with common ranges from 0.56 to 8 mg/kg/day.

Protocol for Long-Term Use

For patients undergoing long-term systemic therapy, a procedural approach to discontinuation is utilized. Treatment is concluded via gradual dose reduction (tapering) rather than an abrupt cessation. This process is intended to allow the body to adjust to the withdrawal of the exogenous corticosteroid. Conversely, topical application generally does not involve occlusive bandaging unless directed by a healthcare professional.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Microsona

Microsona, which contains the active ingredient Hydrocortisone, belongs to a class of topical corticosteroids that have been extensively studied over many decades. Research has focused on studies that explored inflammatory and irritative states associated with certain skin conditions. The overall body of evidence is large and has been summarized in major systematic reviews by independent scientific organizations.


Evidence for Use in Plaque Psoriasis

The research examining Microsona and similar topical corticosteroids for plaque psoriasis includes many short-term Randomized Controlled Trials (RCTs). These studies primarily included adult patients with the condition and were used to explore how symptoms change over defined time intervals.

Researchers focused on quantifying changes in outcomes related to physical discomfort, specifically the visible signs of the condition such as scaling, redness, and plaque thickness. The studies monitored these changes using specific clinical assessment tools, such as the Investigator's Global Assessment (IGA), which helps categorize skin status based on defined levels (often categorized as 'clear' or 'almost clear' status).

When compared to a non-active base or placebo, studies monitored assessment scores which showed differences between the two groups. The overall evidence contributes to the understanding of short-term symptom patterns in conditions involving periods of heightened symptoms.


Assessing the Quality and Consistency of Evidence

The overall evidence level for the initial short-term management of the signs of plaque psoriasis is generally labeled as High based on the numerous studies available, which have been synthesized in systematic reviews. However, the quality of individual studies and the consistency of their findings evidence quality varies across studies.

Regulatory reviews have noted that the clinical development of topical steroids often did not align with modern methodological standards in all cases. This means that while the data show patterns related to symptom evolution, the evidence quality varies across studies, leading to some mixed findings in reported results across the broader class of medicines.


Long-Term Studies and Follow-up Data

Research exploring the long-term management of chronic plaque psoriasis with Microsona or similar topical corticosteroids is limited. Most of the pivotal trials that focused on treatment results had follow-up durations that were limited to short periods, generally 2 to 4 weeks, with few extending to a year or longer.

Studies that have examined patient-reported experiences and the overall duration of outcomes beyond the short-term treatment phase indicate that a strategy of intermittent use was associated with observations of longer periods of symptom stability in some patients. However, long-term effects are not fully established with respect to maintaining skin clarity and addressing disease recurrence.

Key Studies & References Management of Psoriasis in Adults (SW London Integrated Medicines Optimisation Guideline, referencing MHRA advice and NICE principles)

Frequently Asked Questions (FAQ)

Common questions about Microsona (FAQ)


Q: Is Microsona used to treat pain?

Microsona is primarily indicated for the management of symptoms associated with certain inflammatory and autoimmune conditions, according to its approved labeling. The specific use of the medication is determined by a healthcare provider based on the diagnosed condition.


Q: How should I take Microsona for the best results?

The way Microsona should be taken, including the amount and frequency, is based entirely on the specific dosage regimen prescribed by a healthcare provider. Following the detailed instructions provided by the prescribing professional and the official product labeling is essential. Patients should not change their regimen without medical consultation.


Q: Can Microsona be used during pregnancy?

The use of Microsona during pregnancy should only occur if the potential benefit justifies the potential risk to the fetus, as determined by a healthcare provider. Limited data on human pregnancy exposure suggests potential risks, but this must be discussed in detail with a physician who is aware of the individual patient's medical history.


Q: Is Microsona a type of antibiotic?

No, Microsona is not an antibiotic. It belongs to a class of medications known as immunosuppressants or disease-modifying agents. It works by modulating the body's immune system rather than targeting bacteria.


How should Microsona be stored and disposed of?

How to Store and Dispose of Microsona?

Official regulatory documents define strict conditions for the storage and disposal of Microsona to maintain its stability and ensure safety.

Required Storage Conditions

Microsona must be stored at controlled room temperature, maintaining a range between 20 C and 25 C (68 F and 77 F). The product must be protected from freezing, excessive heat, and moisture. It is required to keep the medicine in its original container, tightly closed.

Safety and Disposal

To prevent accidental exposure, Microsona must be stored out of the sight and reach of children and pets. For disposal, unused or expired product should be returned via an approved drug take-back program. If a program is unavailable, disposal must follow official guidelines, which instruct against flushing the medicine down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Microsona found in:

A-Z Index: